% | $
Quotes you view appear here for quick access.

CytRx Corporation Message Board

  • mrshashaberry mrshashaberry Jan 29, 2013 10:24 AM Flag

    Great in depth article on CYTR geared towards sophisticated investors that need tax writeoffs
    Put out by Accesswire. This piece of brilliant journalism uncovers the following information that investors need to know: CytRx has a "robust clinical pipeline" and CytRx "appears to be trading at a substantial discount to many of its peers". It also implies that CytRx compares favorably to "public companies targeting the oncology space, from Onyx Pharmaceuticals Inc.’s (NASDAQ:ONXX) Carfilzomib to Amgen Inc.’s (NASDAQ:AMGN) OncoVex" because "many of these compounds rely on testing and proving completely new approaches to cancer treatment, and involve substantial investment in safety and efficacy testing" while CytRx works by "simply modifying an existing chemotherapy agent, doxorubicin". These fly by night oncology companies- Amgen and Onyx- must be jealous of the sound and productive, value for money, approach taken by Max Bialystock.

    This must be a very unbiased source since their website says:
    Welcome to Accesswire
    Where traditional dissemination methods combine with Social Media to produce guaranteed results. It’s the Smarter way to access the media and gain the coverage and exposure that you need.
    Join 1,000's of other Public and Private companies that make Accesswire one of the best and most cost effective press release dissemination services in the industry! [Note: I did not add the exclamation point'; it was already there].

    Wait a minute...... Max Bialystock? Is that you trying to pump up the stock price before another share offering, or maybe before this year's comp formula is locked down? Oh Mr. Bialystock, how could you? And you seemed like such a genuine, nice old man when I saw your online and heard you say that your drugs are "saving lives". Oh Max!

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.60+0.02(+0.78%)May 23 4:00 PMEDT